Wockhardt Receives Warning Letter Over Sterility, Data Integrity Concerns
Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls.
Source: International Pharmaceutical Regulatory Monitor